Global /India /Healthcare /Drug Manufacturers - Specialty & Generic /LUPIN
chevron_leftBack

Lupin Ltd.

LUPIN
NSE: LUPIN Delayed
2,089.50INR 2.1%
24.44 USD
As of 24 April 2025, Lupin Ltd. has a market cap of $10.95B USD, ranking #1579 globally and #100 in India. It ranks #139 in the Healthcare sector, and #18 in the Drug Manufacturers - Specialty & Generic industry.
Global Rank
1579
Country Rank
100
Sector Rank
139
Industry Rank
18
Key Stats
Market Cap
$10.95BUSD
934.54B INR
Enterprise Value
$11.0BUSD
940.62B INR
Revenue (TTM)
$2.58BUSD
220.02B INR
EBITDA (TTM)
$595.32MUSD
50.9B INR
Net Income (TTM)
$336.17MUSD
28.69B INR
EBITDA Margin
23%
Profit Margin
13%
PE Ratio
32.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Vinita Gupta open_in_new
Employees
19,210
Founded
1968
Website
lupin.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
2.1% 8% -1.2% -2.3% -2% 30%
Upcoming Earnings
Earnings Date
Tue, May 6

Markets

Exchange Ticker Price
National Stock Exchange of India
MIC: XNSE
PRIMARY
LUPIN
Lupin Ltd
ISIN: INE326A01037
Shares Out.:
456.565M1 Shares Float: 241.133M2
TV:
SA:
YF:
GF:
BA:
MS:
2.09K INR
Bombay Stock Exchange
MIC: XBOM
500257 (LUPIN)
Lupin Ltd
ISIN: INE326A01037
TV:
SA:
YF:
GF:
BA:
MS:
2.09K INR
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Lupin Ltd.

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women’s health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Similar Companies

Industry: Drug Manufacturers - Specialty & Generic (India)
Name
Market Cap diff.
Sun Pharmaceutical Industries Ltd.
SUNPHARMA
$49.13B
4.19T INR
349%
Divi's Laboratories Ltd.
DIVISLAB
$18.39B
1.57T INR
68%
Cipla Ltd.
CIPLA
$14.46B
1.23T INR
32%
Torrent Pharmaceuticals Ltd.
TORNTPHARM
$13.23B
1.13T INR
21%
Mankind Pharma Ltd.
MANKIND
$12.47B
1.06T INR
14%
Industry: Drug Manufacturers - Specialty & Generic (Global)
Name
Market Cap diff.
Zoetis Inc.
ZTS
$67.32B
515%
Merck KGaA
MRK
$59.42B
52.43B EUR
443%
Takeda Pharmaceutical Company Ltd.
4502
$46.31B
6.6T JPY
323%
Haleon plc
HLN
$45.57B
34.34B GBP
316%
Galderma Group AG
GALD
$23.06B
19.13B CHF
111%